

**Amendments to the Claims:**

**This listing of claims will replace all prior versions, and listings, of claims in the application:**

**Listing of Claims:**

Claim 1. (Currently Amended): A method for treating neuropathic pain in a patient in need thereof comprising administering to the patient a composition comprising an amount of an opioid antagonist effective to alleviate the neuropathic pain, an opioid agonist and optionally a pharmaceutically acceptable carrier or excipient.

Claim 2. (Cancelled):

Claim 3. (Cancelled):

Claim 4. (Currently Amended): The method of claim [2] 1 wherein the [~~excitatory~~] opioid [~~receptor~~] antagonist or the agonist is present as a pharmaceutically acceptable salt.

Claim 5. (Withdrawn Currently Amended): The method of claim 1 [~~or 2~~] wherein the antagonist is naloxone.

Claim 6. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the antagonist is naltrexone.

Claim 7. (Withdrawn Currently Amended): The method of claim 1 [~~or 2~~] wherein the antagonist is nalmefene.

Claim 8. (Currently Amended): The method of claim [2] 1 wherein the amount of the agonist is an analgesic or a subanalgesic amount.

Claim 9. (Currently Amended): The method of claim [2] 1 wherein the agonist is morphine,

hydrocodone, oxycodone, codeine, fentanyl, alfentanil, hydromorphone, meperidine, methadone, oxymorphone, propoxyphene, or tramadol.

Claim 10. (Currently Amended): The method of claim [2] 1 wherein the agonist is morphine.

Claim 11. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the agonist is hydrocodone.

Claim 12. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the agonist is oxycodone.

Claim 13. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the agonist is tramadol.

Claim 14. (Currently Amended): The method of claim [2] 1 wherein the antagonist is naltrexone and the agonist is morphine.

Claim 15. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is naltrexone and the agonist is oxycodone.

Claim 16. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is naltrexone and the agonist is hydrocodone.

Claim 17. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is naltrexone and the agonist is tramadol.

Claim 18. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is nalmeferene and the agonist is morphine.

Claim 19. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is nalmefene and the agonist is oxycodone.

Claim 20. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is nalmefene and the agonist is hydrocodone.

Claim 21. (Withdrawn Currently Amended): The method of claim [2] 1 wherein the antagonist is nalmefene and the agonist is tramadol.

Claim 22. (Currently Amended): The method of claim 1 [~~or~~ 2] wherein the composition further comprises a therapeutically effective amount of at least one anticonvulsant.

Claim 23. (Currently Amended): The method of claim 1 [~~or~~ 2] wherein the composition further comprises an anticonvulsant that is lamotrigine, gabapentin, valproic acid, topiramate, famotodine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethosuximide, methsuximide, phensuximide, trimethadione, benzodiazepine, phenacetamide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan, or L-5-hydroxytryptophan.

Claim 24. (Currently Amended): The method of claim 1 [~~or~~ 2] wherein the composition further comprises a therapeutically effective amount of at least one non-narcotic analgesic.

Claim 25. (Currently Amended): The method of claim 1 [~~or~~ 2] wherein the composition further comprises a therapeutically effective amount of non-steroidal anti-inflammatory drug.

Claim 26. (Currently Amended): The method of claim 1 [~~or~~ 2] wherein the composition further comprises a nonsteroidal anti-inflammatory drug that is aspirin, diclofenac, diflusal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac,

meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, or zomepirac.

Claim 27. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises tricyclic antidepressant that is amitriptyline, imipramine, desipramine or nortriptyline.

Claim 28. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises a therapeutically effect amount of at least one glutamate receptor antagonist.

Claim 29. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises a glutamate receptor antagonist that is that is ketamine, MK801, memantine, dextromethorphan, dextrophan, LY293558, LY382884, amantadine, agmatine, aptiganel, gavestinel, selfotel, 7-chlorokynurenate, MRZ 2/579, MDL 105,519, riluzole, CPP, AP5, APV, NBQX, CNQX or trans-ACPD.

Claim 30. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises a therapeutically effective amount of at least one anti-dynorphin agent.

Claim 31. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises an anti-dynorphin agent that is anti-dynorphin antibodies, soluble kappa opioid receptors, or soluble kappa opioid receptor fusion proteins.

Claim 32. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises a therapeutically effective amount of at least one nicotinic receptor antagonist.

Claim 33. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises a therapeutic effective amount of at least one local anesthetic.

Claim 34. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises a local anesthetic that is bupivacaine hydrochloride, chloroprocaine hydrochloride,

dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, lidocaine, lidocaine hydrochloride, mepivacaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride tetracaine, or tetracaine hydrochloride.

Claim 35. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises at least one colloidal dispersion system.

Claim 36. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises at least one additive or preservative.

Claim 37. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises at least one pharmaceutically acceptable diluent.

Claim 38. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises at least one binder.

Claim 39. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition further comprises at least one plasticizer.

Claim 40. (Cancelled):

Claim 41. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition is administered orally to the patient.

Claim 42. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition is administered intravenously to the patient.

Claim 43. (Currently Amended): The method of claim 1 [~~or 2~~] wherein the composition is administered intrathecally or epidurally to the patient.

Claim 44. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the composition is administered intramuscularly to the patient.

Claim 45. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the composition is administered subcutaneously to the patient.

Claim 46. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the composition is administered perineurally to the patient.

Claim 47. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the composition is administered intradermally to the patient.

Claim 48. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the composition is administered topically or transcutaneously to the patient.

Claim 49. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the patient is a mammal.

Claim 50. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the patient is a human.

Claim 51. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the administration is from one time daily to four times daily.

Claim 52. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the administration is from two times daily to four times daily.

Claim 53. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the administration is from one time daily to two times daily.

Claim 54. (Currently Amended): The method of claim 1 [~~or~~-2] wherein alleviation of the neuropathic pain is indicated by alleviation of allodynia.

Claim 55. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein alleviation of the neuropathic pain is indicated by alleviation of hyperalgesia.

Claim 56. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein alleviation of the neuropathic pain is indicated by alleviation of spontaneous burning pain.

Claim 57. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein alleviation of the neuropathic pain is indicated by alleviation of phantom pain.

Claim 58. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein alleviation of the neuropathic pain is indicated by alleviation of hyperesthesia.

Claim 59. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with migraine.

Claim 60. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with diabetes.

Claim 61. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with diabetic neuropathy.

Claim 62. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with shingles.

Claim 63. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with burn injury.

Claim 64. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with ophthalmic injury.

Claim 65. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with oral nerve injury or damage.

Claim 66. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with oral nerve injury and wherein the oral nerve injury is caused by endodontic procedures.

Claim 67. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with sensory nerve injury or damage.

Claim 68. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with reflex sympathetic dystrophy (RSD).

Claim 69. (Withdrawn Currently Amended): The method claim 1 [~~or~~-2] wherein the neuropathic pain is associated with post-herpetic neuralgia.

Claim 70. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with arthritis.

Claim 71. (Withdrawn Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is associated with cancer.

Claim 72. (Currently Amended): The method of claim 1 [~~or~~-2] wherein the neuropathic pain is not associated with the administration of a therapeutic agent.

Claim 73. (Original): A method for treating neuropathic pain in a patient in need thereof



comprising administering to the patient a composition an amount of naltrexone, nalmeferone or naloxone from about 0.000001 mg to less than about 1.0 mg and an amount of morphine, oxycodone, oxymorphone, hydrocodone or tramadol from about 0.1 mg to about 300 mg.

Claim 74. (Original): A method for treating neuropathic pain in a patient in need thereof comprising administering to the patient a composition an amount of naltrexone, nalmeferone or naloxone from about 1 fg to less than about 1 ng and an amount of morphine, oxycodone, oxymorphone, hydrocodone or tramadol from about 0.1 mg to about 300 mg.

Claim 75. (Withdrawn): A method for treating hyperesthesia in a patient in need thereof comprising administering to the patient a composition comprising an amount of an opioid antagonist effective to alleviate the hyperesthesia.

Claim 76. (Withdrawn): A method for treating hyperalgesia in a patient in need thereof comprising administering to the patient a composition comprising an amount of an opioid antagonist effective to alleviate the hyperalgesia.

Claim 77. (Original): A method for treating allodynia in a patient in need thereof comprising administering to the patient a composition comprising an amount of an opioid antagonist effective to alleviate the allodynia.

Claim 78. (Withdrawn): A method for treating spontaneous burning pain in a patient in need thereof comprising administering to the patient a composition comprising an amount of an opioid antagonist effective to alleviate the spontaneous burning pain.

Claim 79. (Withdrawn): A method for treating phantom pain in a patient in need thereof comprising administering to the patient a composition comprising an amount of an opioid antagonist effective to alleviate the phantom pain.

Claim 80. (Original): A method for treating pain in a subject with neuropathic pain comprising

administering to the subject an opioid agonist and an opioid antagonist, wherein the antagonist is administered in an amount effective to enhance the neuropathic pain-alleviating potency of the agonist.

Claim 81. (Withdrawn): The method of claim 80 wherein the potency of the agonist is measured by alleviation of hyperesthesia.

Claim 82. (Withdrawn): The method of claim 80 wherein the potency of the agonist is measured by alleviation of hyperalgesia.

Claim 83. (Original): The method of claim 80 wherein the potency of the agonist is measured by alleviation of allodynia.

Claim 84. (Withdrawn): The method of claim 80 wherein the potency of the agonist is measured by alleviation of spontaneous burning pain.

Claim 85. (Withdrawn): The method of claim 80 wherein the potency of the agonist is measured by alleviation of phantom pain.

Claim 86. (Withdrawn): The method of claim 80 wherein the amount of the agonist is an analgesic or subanalgesic amount.

Claim 87. (Original): The method of claim 80 wherein the agonist is morphine.

Claim 88. (Withdrawn): The method of claim 80 wherein the agonist is oxycodone.

Claim 89. (Withdrawn): The method of claim 80 wherein the agonist is hydrocodone.

Claim 90. (Withdrawn): The method of claim 80 wherein the agonist is oxymorphone.

Claim 91. (Withdrawn): The method of claim 80 wherein the agonist is hydromorphone.

Claim 92. (Withdrawn): The method of claim 80 wherein the agonist is tramadol.

Claim 93. (Withdrawn): The method of claim 80 wherein the antagonist is nalmefene.

Claim 94. (Withdrawn): The method of claim 80 wherein the antagonist is naltrexone.

Claim 95. (Withdrawn): The method of claim 80 wherein the antagonist is naloxone.

Claim 96. (Original): The method of claim 80 wherein the mode of administration is oral.

Claim 97. (Original): The method of claim 80 wherein the mode of administration is intravenous.

Claim 98. (Original): The method of claim 80 wherein the mode of administration is intrathecal or epidural.

Claim 99. (Original): The method of claim 80 wherein the mode of administration is intramuscular.

Claim 100. (Original): The method of claim 80 wherein the mode of administration is subcutaneous.

Claim 101. (Original): The method of claim 80 wherein the mode of administration is perineural.

Claim 102. (Original): The method of claim 80 wherein the mode of administration is intradermal.

Claim 103. (Original): The method of claim 80 wherein the mode of administration is topical.

Claim 104. (Withdrawn): The method of claim 80 wherein the mode of administration is transcutaneous.

Claim 105. (Withdrawn): The method of claim 80 wherein the agonist is oxycodone and the antagonist is naltrexone.

Claim 106. (Original): The method of claim 80 wherein the agonist is morphine and the antagonist is naltrexone.

Claim 107. (Withdrawn): The method of claim 80 wherein the agonist is oxycodone and the antagonist is nalmeferne.

Claim 108. (Withdrawn): The method of claim 80 wherein the agonist is morphine and the antagonist is nalmeferne.

Claim 109. (Withdrawn): The method of claim 80 wherein the agonist is oxycodone and the antagonist is naloxone.

Claim 110. (Withdrawn): The method of claim 80 wherein the agonist is morphine and the antagonist is naloxone.

Claim 111. (Original): The method of claim 80 wherein the amount of the agonist is from about 0.1 mg to about 300 mg.

Claim 112. (Original): The method of claim 80 wherein the amount of the antagonist is from about 0.000001 mg to about or less than about 1 mg.

Claim 113. (Original): The method of claim 80 wherein the amount of the antagonist is

additionally effective to alleviate a tolerance, dependence, addiction or withdrawal effect of the agonist.

Claim 114. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least 50 to 100 fold less than the amount of the agonist administered.

Claim 115. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least 100 to 1000 fold less than the amount of the agonist administered.

Claim 116. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 40 fold less than the amount of the agonist administered.

Claim 117. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 50 fold less than the amount of the agonist administered.

Claim 118. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 100 fold less than the amount of the agonist administered.

Claim 119. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 1000 fold less than the amount of the agonist administered.

Claim 120. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 10,000 fold less than the amount of the agonist administered.

Claim 121. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 100,000 fold less than the amount of the agonist administered.

Claim 122. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 1,000,000 fold less than the amount of the agonist administered.

Claim 123. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 10,000,000 fold less than the amount of the agonist administered.

Claim 124. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 100,000,000 fold less than the amount of the agonist administered.

Claim 125. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 1,000,000,000 fold less than the amount of the agonist administered.

Claim 126. (Original): The method of claim 80 wherein the amount of the antagonist administered is at least more than 10,000,000,000 fold less than the amount of the agonist administered.

Claim 127. (Original): A method for enhancing the potency of an opioid agonist comprising administering to a subject with neuropathic pain an amount of the agonist and an amount of an opioid antagonist effective to enhance the neuropathic pain-alleviating potency of the agonist.

Claim 128. (Withdrawn): The method of claim 127 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of hyperesthesia.

Claim 129. (Withdrawn): The method of claim 127 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of hyperalgesia.

Claim 130. (Original): The method of claim 127 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of allodynia.

Claim 131. (Withdrawn): The method of claim 127 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of spontaneous burning pain.

Claim 132. (Withdrawn): The method of claim 127 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of phantom pain.

Claim 133. (Original): The method of claim 127 wherein the amount of the agonist is an analgesic or subanalgesic amount.

Claim 134. (Withdrawn): The method of claim 127 wherein the agonist is morphine.

Claim 135. (Withdrawn): The method of claim 127 wherein the agonist is oxycodone.

Claim 136. (Withdrawn): The method of claim 127 wherein the agonist is hydrocodone.

Claim 137. (Withdrawn): The method of claim 127 wherein the agonist is oxymorphone.

Claim 138. (Withdrawn): The method of claim 127 wherein the agonist is hydromorphone.

Claim 139. (Withdrawn): The method of claim 127 wherein the agonist is tramadol.

Claim 140. (Withdrawn): The method of claim 127 wherein the antagonist is nalmefene.

Claim 141. (Original): The method of claim 127 wherein the antagonist is naltrexone.

Claim 142. (Withdrawn): The method of claim 127 wherein the antagonist is naloxone.

Claim 143. (Original): The method of claim 127 wherein the mode of administration is oral.

Claim 144. (Original): The method of claim 127 wherein the mode of administration is intravenous.

Claim 145. (Original): The method of claim 127 wherein the mode of administration is intrathecal or epidural.

Claim 146. (Original): The method of claim 127 wherein the mode of administration is intramuscular.

Claim 147. (Original): The method of claim 127 wherein the mode of administration is subcutaneous.

Claim 148. (Original): The method of claim 127 wherein the mode of administration is perineural.

Claim 149. (Original): The method of claim 127 wherein the mode of administration is intradermal.

Claim 150. (Original): The method of claim 127 wherein the mode of administration is topical.

Claim 151. (Original): The method of claim 127 wherein the mode of administration is transcutaneous.

Claim 152. (Withdrawn): The method of claim 127 wherein the agonist is oxycodone and the antagonist is naltrexone.

Claim 153. (Original): The method of claim 127 wherein the agonist is morphine and the antagonist is naltrexone.



Claim 154. (Withdrawn): The method of claim 127 wherein the agonist is oxycodone and the antagonist is nalmefene.

Claim 155. (Withdrawn): The method of claim 127 wherein the agonist is morphine and the antagonist is nalmefene.

Claim 156. (Withdrawn): The method of claim 127 wherein the agonist is oxycodone and the antagonist is naloxone.

Claim 157. (Withdrawn): The method of claim 127 wherein the agonist is morphine and the antagonist is naloxone.

Claim 158. (Original): The method of claim 127 wherein the amount of the agonist is from about 0.1 mg to about 300 mg.

Claim 159. (Original): The method of claim 127 wherein the amount of the antagonist is from about 0.000001 mg to about or less than about 1 mg.

Claim 160. (Original): The method of claim 127 wherein the amount of the antagonist is additionally effective to alleviate a tolerance, dependence, addiction or withdrawal effect of the agonist.

Claim 161. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least 50 to 100 fold less than the amount of the agonist administered.

Claim 162. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least 100 to 1000 fold less than the amount of the agonist administered.

Claim 163. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 40 fold less than the amount of the agonist administered.

Claim 164. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 50 fold less than the amount of the agonist administered.

Claim 165. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 100 fold less than the amount of the agonist administered.

Claim 166. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 1000 fold less than the amount of the agonist administered.

Claim 167. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 10,000 fold less than the amount of the agonist administered.

Claim 168. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 100,000 fold less than the amount of the agonist administered.

Claim 169. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 1,000,000 fold less than the amount of the agonist administered.

Claim 170. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 10,000,000 fold less than the amount of the agonist administered.

Claim 171. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 100,000,000 fold less than the amount of the agonist administered.

Claim 172. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 1,000,000,000 fold less than the amount of the agonist administered.

Claim 173. (Original): The method of claim 127 wherein the amount of the antagonist administered is at least more than 10,000,000,000 fold less than the amount of the agonist administered.

Claim 174. (Withdrawn): A composition for administration to a subject with neuropathic pain comprising an analgesic or subanalgesic amount of an opioid agonist and an amount of an opioid antagonist effective to enhance the neuropathic pain-alleviating potency of the agonist.

Claim 175. (Withdrawn): The composition of claim 174 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of hyperesthesia.

Claim 176. (Withdrawn): The composition of claim 174 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of hyperalgesia.

Claim 177. (Withdrawn): The composition of claim 174 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of allodynia.

Claim 178. (Withdrawn): The composition of claim 174 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of spontaneous burning pain.

Claim 179. (Withdrawn): The composition of claim 174 wherein the neuropathic pain-alleviating potency of the agonist by the antagonist is measured by alleviation of phantom pain.

Claim 180. (Withdrawn): The composition of claim 174 wherein the amount of the agonist is an analgesic or subanalgesic amount.

Claim 181. (Withdrawn): The composition of claim 174 wherein the agonist is morphine.

Claim 182. (Withdrawn): The composition of claim 174 wherein the agonist is oxycodone.

Claim 183. (Withdrawn): The composition of claim 174 wherein the antagonist is hydrocodone.

Claim 184. (Withdrawn): The composition of claim 174 wherein the agonist is oxymorphone.

Claim 185. (Withdrawn): The composition of claim 174 wherein the agonist is hydromorphone.

Claim 186. (Withdrawn): The composition of claim 174 wherein the agonist is tramadol.

Claim 187. (Withdrawn): The composition of claim 174 wherein the antagonist is nalmefene.

Claim 188. (Withdrawn): The composition of claim 174 wherein the antagonist is naltrexone.

Claim 189. (Withdrawn): The composition of claim 174 wherein the antagonist is naloxone.

Claim 190. (Withdrawn): The composition of claim 174 wherein the mode of administration is oral.

Claim 191. (Withdrawn): The composition of claim 174 wherein the mode of administration is intravenous.

Claim 192. (Withdrawn): The composition of claim 174 wherein the mode of administration is intrathecal or epidural.

Claim 193. (Withdrawn): The composition of claim 174 wherein the mode of administration is intramuscular.

Claim 194. (Withdrawn): The composition of claim 174 wherein the mode of administration is subcutaneous.

Claim 195. (Withdrawn): The composition of claim 174 wherein the mode of administration is perineural.

Claim 196. (Withdrawn): The composition of claim 174 wherein the mode of administration is intradermal.

Claim 197. (Withdrawn): The composition of claim 174 wherein the mode of administration is topical.

Claim 198. (Withdrawn): The composition of claim 174 wherein the mode of administration is transcutaneous.

Claim 199. (Withdrawn): The composition of claim 174 wherein the agonist is oxycodone and the antagonist is naltrexone.

Claim 200. (Withdrawn): The composition of claim 174 wherein the agonist is morphine and the antagonist is naltrexone.

Claim 201. (Withdrawn): The composition of claim 174 wherein the agonist is oxycodone and the antagonist is nalmefene.

Claim 202. (Withdrawn): The composition of claim 174 wherein the agonist is morphine and the antagonist is nalmefene.

Claim 203. (Withdrawn): The composition of claim 174 wherein the agonist is oxycodone and the antagonist is naloxone.

Claim 204. (Withdrawn): The composition of claim 174 wherein the agonist is morphine and the antagonist is naloxone.

Claim 205. (Withdrawn): A composition of claim 174 wherein the amount of the agonist is from about 0.1 mg to about 300 mg.

Claim 206. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist is from about 0.000001 mg to about or less than about 1 mg.

Claim 207. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist is additionally effective to attenuate the tolerance, dependence, addiction or withdrawal effects of the agonist.

Claim 208. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least 50 to 100 fold less than the amount of the agonist administered.

Claim 209. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least 100 to 1000 fold less than the amount of the agonist administered.

Claim 210. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 40 fold less than the amount of the agonist administered.

Claim 211. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 50 fold less than the amount of the agonist administered.

Claim 212. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 100 fold less than the amount of the agonist administered.

Claim 213. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 1000 fold less than the amount of the agonist administered.

Claim 214. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 10,000 fold less than the amount of the agonist administered.

Claim 215. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 100,000 fold less than the amount of the agonist administered.

Claim 216. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 1,000,000 fold less than the amount of the agonist administered.

Claim 217. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 10,000,000 fold less than the amount of the agonist administered.

Claim 218. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 100,000,000 fold less than the amount of the agonist administered.

Claim 219. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 1,000,000,000 fold less than the amount of the agonist administered.

Claim 220. (Withdrawn): The composition of claim 174 wherein the amount of the antagonist administered is at least more than 10,000,000,000 fold less than the amount of the agonist administered.

Claim 221. (Withdrawn): A composition for administration to a neuropathic pain patient comprising an amount of an opioid antagonist effective to enhance the neuropathic pain-alleviating potency of an endogenous opioid agonist.

Claim 222. (Withdrawn): The composition of claim 221 additionally comprising an opioid agonist and optionally a pharmaceutically acceptable carrier or excipient.

Claim 223. (Withdrawn): The composition of claim 221 wherein the amount of the antagonist is less than an effective antagonistic amount.

Claim 224. (Withdrawn): The composition of claim 221 or 222 wherein the antagonist or the agonist is present as a pharmaceutically acceptable salt.

Claim 225. (Withdrawn): The composition of claim 221 or 222 wherein the antagonist is naloxone.

Claim 226. (Withdrawn): The composition of claim 221 or 222 wherein the antagonist is naltrexone.

Claim 227. (Withdrawn): The composition of claim 221 or 222 wherein the antagonist is nalmefene.

Claim 228. (Withdrawn): The composition of claim 222 wherein the amount of the agonist is an analgesic or a subanalgesic amount.

Claim 229. (Withdrawn): The composition of claim 222 wherein the agonist is morphine, hydrocodone, oxycodone, codeine, fentanyl, alfentanil, hydromorphone, meperidine, methadone, oxymorphone, propoxyphene, or tramadol.



Claim 230. (Withdrawn): The composition of claim 222 wherein the agonist is morphine.

Claim 231. (Withdrawn): The composition of claim 222 wherein the agonist is hydrocodone.

Claim 232. (Withdrawn): The composition of claim 222 wherein the agonist is oxycodone.

Claim 233. (Withdrawn): The composition of claim 222 wherein the agonist is tramadol.

Claim 234. (Withdrawn): The composition of claim 222 wherein the antagonist is naltrexone and the agonist is morphine.

Claim 235. (Withdrawn): The composition of claim 222 wherein the antagonist is naltrexone and the agonist is oxycodone.

Claim 236. (Withdrawn): The composition of claim 222 wherein the antagonist is naltrexone and the agonist is hydrocodone.

Claim 237. (Withdrawn): The composition of claim 222 wherein the antagonist is naltrexone and the agonist is tramadol.

Claim 238. (Withdrawn): The composition of claim 222 wherein the antagonist is nalmefene and the agonist is morphine.

Claim 239. (Withdrawn): The composition of claim 222 wherein the antagonist is nalmefene and the agonist is oxycodone.

Claim 240. (Withdrawn): The composition of claim 222 wherein the antagonist is nalmefene and the agonist is hydrocodone.

Claim 241. (Withdrawn): The composition of claim 222 wherein the antagonist is nalmeferine and the agonist is tramadol.

Claim 242. (Withdrawn): The composition of claim 221 or 222 further comprising a therapeutically effective amount of at least one anticonvulsant.

Claim 243. (Withdrawn): The composition of claim 221 or 222 further comprising an anticonvulsant that is lamotrigine, gabapentin, valproic acid, topiramate, famotidine, phenobarbital, diphenylhydantoin, phenytoin, mephenytoin, ethosuximide, mephobarbital, primidone, carbamazepine, ethosuximide, methsuximide, phenisuximide, trimethadione, benzodiazepine, phenacetamide, acetazolamide, progabide, clonazepam, divalproex sodium, magnesium sulfate injection, metharbital, paramethadione, phenytoin sodium, valproate sodium, clobazam, sulthiame, dilantin, diphenylan, or L-5-hydroxytryptophan.

Claim 244. (Withdrawn): The composition of claim 221 or 222 further comprising a therapeutically effective amount of at least one non-narcotic analgesic.

Claim 245. (Withdrawn): The composition of claim 221 or 222 further comprising a therapeutically effective amount of a non-narcotic analgesic that is a nonsteroidal anti-inflammatory drug.

Claim 246. (Withdrawn): The composition of claim 221 or 222 further comprising a nonsteroidal anti-inflammatory drug that is aspirin, diclofenac, diflusal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin or zomepirac.

Claim 247. (Withdrawn): The composition of claim 221 or 222 further comprising a tricyclic antidepressant that is amitriptyline, imipramine, desipramine or nortriptyline.

Claim 248. (Withdrawn): The composition of claim 221 or 222 further comprising a therapeutically effect amount of at least one glutamate receptor antagonist.

Claim 249. (Withdrawn): The composition of claim 221 or 222 further comprising a glutamate receptor antagonist that is ketamine, MK801, memantine, dextromethorphan, dextrorphan, LY293558, LY382884, amantadine, agmatine, aptiganel, gavestinel, selfotel, 7-chlorokynurenate, MRZ 2/579, MDL 105,519, riluzole, CPP, AP5, APV, NBQX, CNQX or trans-ACPD.

Claim 250. (Withdrawn): The composition of claim 221 or 222 further comprising a therapeutically effective amount of at least one anti-dynorphin agent.

Claim 251. (Withdrawn): The composition of claim 221 or 222 further comprising an anti-dynorphin agent that is anti-dynorphin antibodies, soluble kappa opioid receptors, or soluble kappa opioid receptor fusion proteins.

Claim 252. (Withdrawn): The composition of claim 221 or 222 further comprising a therapeutic effective amount of at least one local anesthetic.

Claim 253. (Withdrawn): The method of claim 221 or 222 wherein the composition further comprises a therapeutically effective amount of at least one nicotinic receptor antagonist.

Claim 254. (Withdrawn): The composition of claim 221 or 222 further comprising a local anesthetic that is bupivacaine hydrochloride, chloroprocaine hydrochloride, dibucaine, dibucaine hydrochloride, etidocaine hydrochloride, lidocaine, lidocaine hydrochloride, mepivacaine hydrochloride, piperocaine hydrochloride, prilocaine hydrochloride, procaine hydrochloride, propoxycaine hydrochloride tetracaine, or tetracaine hydrochloride.

Claim 255. (Withdrawn): The composition of claim 221 or 222 further comprising at least one colloidal dispersion system.

Claim 256. (Withdrawn): The composition of claim 221 or 222 further comprising at least one additive or preservative.

Claim 257. (Withdrawn): The composition of claim 221 or 222 further comprising at least one pharmaceutically acceptable diluent.

Claim 258. (Withdrawn): The composition of claim 221 or 222 further comprising at least one binder.

Claim 259. (Withdrawn): The composition of claim 221 or 222 further comprising at least one plasticizer.

Claim 260. (Withdrawn): The composition of claim 222 wherein the pharmaceutically acceptable carrier is a controlled release or sustained release agent.

Claim 261. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of oral formulation.

Claim 262. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of intravenous formulation.

Claim 263. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of a intrathecal or epidural formulation.

Claim 264. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of intramuscular formulation.

Claim 265. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of subcutaneous formulation.

Claim 266. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of perineural formulation.

Claim 267. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of intradermal formulation.

Claim 268. (Withdrawn): The composition of claim 221 or 222, wherein the composition is in the form of a topical formulation.

Claim 269. (Withdrawn): The composition of claim 221 or 222 wherein the composition is in the form of a capsule or tablet.

Claim 270. (Withdrawn): The composition of claim 221 or 222 wherein the patient is a mammal.

Claim 271. (Withdrawn): The composition of claim 221 or 222 wherein the patient is a human.

Claim 272. (Withdrawn): A composition for administration to a neuropathic pain patient comprising an amount of naltrexone, nalmeferene or naloxone from about 0.000001 mg to less than about 1.0 mg and an amount of morphine, oxycodone, oxymorphone, hydrocodone or tramadol from about 0.1 mg to about 300 mg.